CH672989A5 - - Google Patents

Download PDF

Info

Publication number
CH672989A5
CH672989A5 CH1788/87A CH178887A CH672989A5 CH 672989 A5 CH672989 A5 CH 672989A5 CH 1788/87 A CH1788/87 A CH 1788/87A CH 178887 A CH178887 A CH 178887A CH 672989 A5 CH672989 A5 CH 672989A5
Authority
CH
Switzerland
Prior art keywords
sod
pharmaceutical formulation
amino acid
combination
formulation according
Prior art date
Application number
CH1788/87A
Other languages
German (de)
English (en)
Inventor
Henry Berger
Crist John Frangakis
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/862,057 external-priority patent/US4976959A/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of CH672989A5 publication Critical patent/CH672989A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CH1788/87A 1986-05-12 1987-05-11 CH672989A5 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86204686A 1986-05-12 1986-05-12
US06/862,057 US4976959A (en) 1986-05-12 1986-05-12 T-PA and SOD in limiting tissue damage

Publications (1)

Publication Number Publication Date
CH672989A5 true CH672989A5 (xx) 1990-01-31

Family

ID=27127662

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1788/87A CH672989A5 (xx) 1986-05-12 1987-05-11

Country Status (13)

Country Link
JP (1) JPH0680015B2 (xx)
AU (1) AU600724B2 (xx)
BE (1) BE1001425A4 (xx)
CH (1) CH672989A5 (xx)
DE (1) DE3715662A1 (xx)
DK (1) DK237187A (xx)
FR (1) FR2600895B1 (xx)
GB (1) GB2194886B (xx)
IE (1) IE59895B1 (xx)
LU (1) LU86875A1 (xx)
NL (1) NL8701113A (xx)
NZ (1) NZ220260A (xx)
SE (1) SE8701921L (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780784B2 (ja) * 1987-10-23 1995-08-30 宇部興産株式会社 微小循環障害に基づく心筋虚血傷害治療薬
NZ230808A (en) * 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
DE4038563A1 (de) * 1990-12-04 1992-06-11 Gruenenthal Gmbh Verwendung von superoxiddismutasen zur prophylaxe und/oder behandlung von organversagen bei risikopatienten mit polytrauma
DE19518625C2 (de) * 1995-05-24 1997-08-07 Buescher Pebueso Beton Verfahren zum Abdichten von Betonrohren und ein für die Durchführung des Verfahrens geeignetes Betonrohr
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
WO2007004869A2 (en) 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
WO2011013668A1 (ja) * 2009-07-27 2011-02-03 国立大学法人新潟大学 虚血性イベントの治療用医薬品組成物
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
DE3382389D1 (de) * 1982-12-14 1991-10-02 South African Inventions Plasminogenaktivator.
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
AT391812B (de) * 1985-05-28 1990-12-10 Wellcome Found Verfahren zur herstellung einer parenteralen t-pa-loesung
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
WO1987006831A1 (en) * 1986-05-15 1987-11-19 Emory University Composition and method for treating a thrombus and embolus

Also Published As

Publication number Publication date
IE871210L (en) 1987-11-12
DK237187D0 (da) 1987-05-11
BE1001425A4 (fr) 1989-10-31
GB8711058D0 (en) 1987-06-17
DE3715662A1 (de) 1987-11-19
NL8701113A (nl) 1987-12-01
AU600724B2 (en) 1990-08-23
LU86875A1 (fr) 1988-01-20
SE8701921L (sv) 1987-11-13
FR2600895A1 (fr) 1988-01-08
JPH0680015B2 (ja) 1994-10-12
SE8701921D0 (sv) 1987-05-11
GB2194886B (en) 1990-04-25
GB2194886A (en) 1988-03-23
FR2600895B1 (fr) 1993-12-24
AU7270487A (en) 1987-11-19
IE59895B1 (en) 1994-04-20
NZ220260A (en) 1990-07-26
JPS6322026A (ja) 1988-01-29
DK237187A (da) 1987-11-13

Similar Documents

Publication Publication Date Title
CH672989A5 (xx)
DE60035987T2 (de) Metabolische intervention mit glp-1 oder seinen biologisch aktiven analogen zur verbesserung der funktion des ischämischen und wiederdurchbluteten gehirns
AT391812B (de) Verfahren zur herstellung einer parenteralen t-pa-loesung
DE3855096T2 (de) Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus
EP0142860B1 (de) Desulfatohirudine, Verfahren zu ihrer Herstellung und pharmazeutische Mittel
DE69433133T2 (de) Lösliches thrombomodulin enthaltende zubereitung
DE3617752C2 (xx)
DE3689943T2 (de) Degradierte Spezies eines Gewebeplasminogenaktivators, pharmazeutische Zubereitung und Verfahren zur Herstellung derselben.
DE60009529T2 (de) Pharmazeutische zusammensetzung aus fibrinolytischem mittel
DE68911061T2 (de) Mittel zur Kontrolle von Thrombenbildungen.
CA1297009C (en) Use of t-pa for the inhibition of damage to jeopardized tissue during reperfusion in a mammal
DE69429816T2 (de) C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
EP0500602A1 (de) Mittel zur neutralisierung der tumorzellen-assoziierten prokoagulant-aktivität.
Jönsson et al. Cardiac muscle cell damage induced by restraint stress
EP0458950B1 (de) K2p pro-stabilisierung
EP0356945B1 (de) Verwendung von Plasminogen-Aktivator-Inhibitor (PAI-2) zur Immunsuppression
EP0743070A2 (de) Verwendung von Protease-Proenzymen und Amylasen als Wirkstoffe in pharmazeutischen Mitteln zur Krebstherapie sowie ihre Herstellung
JPH0273022A (ja) 組織プラスミノーゲン活性化因子を用いた薬学的製剤
DE69833727T2 (de) Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C
DE4430204A1 (de) Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
DE69930419T2 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE60313627T2 (de) Kardioprotektive therapien auf basis von enzymatischer eliminierung von lipidperoxiden durch allenoxid-synthase
AU598239B2 (en) The application of tissue plasminogen activator and oxypurinol in dissolving blood clots and in preventing damage to ischaemic tissue during reperfusion
CA2019098A1 (en) Eyeground disease therapeutic treatment composition
Borreli et al. The co-operative action of hyaluronidase and urokinase on the isoproterenol-induced myocardial infarction in rats

Legal Events

Date Code Title Description
PL Patent ceased